TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01521390
Drug: GSK573719 125 mcg(two strips)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK573719 125 mcg delivered by 2 strip configuration of novel dry powder inhaler
Study: NCT01521390
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, no active ingredient
Study: NCT04221256
Drug: Administration of Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered a placebo prior to paired associative stimulation
Study: NCT03678688
Drug: 3 mg OPC-167832
Normalized name: naphazoline hydrochloride 0.27 MG/ML / pheniramine maleate 3.15 MG/ML [Opcon-A]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral dose of 3 mg OPC-167832 from Day 1 through Day 14.
Study: NCT02959411
Drug: Standard of care diuretic therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual standard of care diuretic therapy for patients hospitalized with acute decompensated heart failure
Study: NCT00329537
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-subcutaneous injection
Study: NCT02192632
Drug: Epiduo- once daily, simple instruction for application
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04711291
Drug: Convert to Envarsus XR once daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convert from tacrolimus immediate release to tacrolimus extended release (Envarsus XR) prescribed dose every 24 hours
Study: NCT00837291
Drug: CF101
Normalized name: CF101
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF101 tablets 1 mg BID
Study: NCT00837291
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets BID
Study: NCT03540524
Drug: GLPG2451 dose regimen A
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG2451 oral suspension, daily.
Study: NCT03540524
Drug: GLPG2451 dose regimen B
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG2451 oral suspension, daily.
Study: NCT03540524
Drug: GLPG2222
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG2222 tablet for oral use, daily.
Study: NCT03540524
Drug: GLPG2737
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG2737 capsules for oral use, daily.
Study: NCT00856687
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, two doses 12 hours apart
Study: NCT03960645
Drug: B/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50/200/25 mg FDC tablet administered orally once daily without regard to food.
Study: NCT03185793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 5 weeks
Study: NCT03185793
Drug: SHR4640
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg SHR4640 once daily for a week, 2.5mg, 5mg or 10mg SHR4640 once daily for 4 weeks
Study: NCT01332552
Drug: GSK2485852 70 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT01332552
Drug: GSK2485852 420 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT01332552
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT01332552
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat dose, once daily for 3 days
Study: NCT01332552
Drug: GSK2485852 420 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat dose, twice daily for 3 days
Study: NCT01332552
Drug: GSK2485852 420 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat dose, TIDfor 3 days
Study: NCT01332552
Drug: GSK2485852 630 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat dose, twice daily for 3 days
Study: NCT03263117
Drug: Sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: The protocol does not specify a particular combination of drugs that must be used for sedation.~The most common drugs utilized for sedation and wide dosing ranges are included in the protocol (i.e., sedation will be provided under the supervision of an anesthesiologist and may use a combination of fentanyl, midazolam, dexmedetomidine infusion (with or without loading dose), and/or low-dose propofol by intermittent bolus or infusion); however, the choice of specific drugs and dosages for achieving conscious sedation or general anesthesia will not be specified by the protocol but will be up to the anesthesiologist.
Study: NCT03263117
Drug: General Anesthesia (GA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The protocol doesn't specify drugs that must be used for GA, the choice of drugs and dosages for achieving general anesthesia will not be specified by the protocol but will be up to the anesthesiologist.~The most common drugs utilized for GA and wide dosing ranges included in the protocol are (GA will be provided under the supervision of an anesthesiologist and induction of anesthesia may be achieved with propofol and/or etomidate; muscle paralysis may be achieved with succinylcholine or non-depolarizing paralytic (rocuronium or vecuronium); and adjuvant lidocaine and fentanyl; if intravenous maintenance of anesthesia is used, it may be achieved by propofol infusion at 50 to 150 mcg/kg/min with redosing of non-depolarizing paralytic and fentanyl as needed; if inhalational maintenance of anesthesia is used it will be achieved with sevoflurane 1% to 2% or desflurane 3% to 6% end-tidal concentration with redosing of non-depolarizing paralytic and fentanyl as needed)
Study: NCT01450007
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml normal saline (intravenous)
Study: NCT00680602
Drug: SSRI (fluoxetine, sertraline, paroxetine, citalopram)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (80mg/day or maximum tolerated dosage) Sertraline (200mg/day or maximum tolerated dosage) Paroxetine (60 mg/day or maximum tolerated dosage) Citalopram (60 mg/day or maximum tolerated dosage)
Study: NCT01450007
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 ml normal saline (perineural)
Study: NCT00712413
Drug: OBMT
Normalized name: Oxbutynin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg twice daily, in combination with bismuth subcitrate potassium (40 mg), metronidazole 125 mg and tetracycline 125 mg HCl. All patients must take 6 capsules of Pylera, in addition to 1 omeprazole twice daily
Study: NCT00703352
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eplerenone (coated tablet) 50mg daily during 12 months.
Study: NCT04313699
Drug: Antiretroviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The cohort will recruit HIV infected participants who are on antiretroviral treatment
Study: NCT03936166
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01596686
Drug: one of two possible colon preparation regimens
Normalized name: Sus scrofa colon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are randomized to receive one of the two different preparation regimens for colonoscopy usually employed in our unit, polyethylene glycol or sodium picosulphate and magnesium citrate
Study: NCT01337752
Drug: BHQ880
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01337752
Drug: BHQ880 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT00001615
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02431442
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02983188
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, 0.3g every time, two times daily
Study: NCT02983188
Drug: Antipsychotic Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic agents prescribed at the discretion of the patients' psychiatrists with respect to patients' conditions. Concomitant use of other psychotropic drugs, including antidepressants, anxiolytics, and mood stabilizers for mood disorders, benzodiazepines and non-benzodiazepines for insomnia, and anticholinergics for extrapyramidal symptoms, was allowed as usual. For those who were under anti-hyperlipidemic, antihypertensive and anti-diabetic treatment, they were allowed to continue their current medications throughout the study.
Study: NCT02709005
Drug: 5% Monolaurin Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monolaurin Vaginal Gel is a clear and colorless, non-sterile glycol-based gel for vaginal administration , and commonly referred to as glycerol monolaurate (GML). Each subject will receive intravaginal gel twice daily for three successive days for a total of 6 doses. There will be 3 clinic visits over 30 days.
Study: NCT01921712
Drug: PUR0200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized single doses of 3 selected doses of PUR0200, compared to a placebo and active comparator
Study: NCT01921712
Drug: PUR0200 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized, single dose of inhaled placebo matched to PUR0200
Study: NCT03616574
Drug: CA102N
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA102N is a covalently bound conjugate of the biological polymer sodium hyaluronate (NaHA) and nimesulide (Nim).
Study: NCT03863405
Drug: Conventional DMARDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: methotrexate, leflunomide, hydroxychloroquine or sulfasalazine
Study: NCT03863405
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT04336709
Drug: Calcipex II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water based intracanal medicament
Study: NCT04336709
Drug: Metapex
Normalized name: metaproterenol sulfate Oral Tablet [Metaprel]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oil based intracanal medicament
Study: NCT03068312
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to IVA tablet.
Study: NCT01755559
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: antimalarial ACT
Study: NCT01349998
Drug: Product 33525
Normalized name: Pyelocalyceal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing for 2 weeks each recurrence for patients with tinea pedis and Daily dosing for 1 week each recurrence for patients with tinea cruris and tinea corporis
Study: NCT02404844
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily oral
Study: NCT01343680
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5ml 10 units/ml IV heparin 3 times per week
Study: NCT01343680
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10ml normal saline IV weekly
Study: NCT00880854
Drug: BCG and CP-675,206
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level -1: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 3 mg/kg I.V. week 3, week 15~Dose level 1: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 6 mg/kg I.V. week 3, week 15~Dose level 2: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 10 mg/kg IV week 3, week 15~Dose level 3: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 15 mg/kg IV week 3, week 15
Study: NCT02792543
Drug: parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (the gold standard treatment) consists of electrolyte supplementation, hydration, and nutrition through a central venous catheter.
Study: NCT03418233
Drug: CardioCell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to the active treatment group will receive transcoronary or trans-bypass graft administration of 30 000 000 cells (suspended in 20 ml of 0.9% NaCl and 5% albumin).~Injection will be performed using a dedicated cell delivery catheter. The cell delivery catheter is a typical coronary balloon catheter that is CE marked (1.2x10 mm balloon, RX system) modified to include cell delivery perforations in the balloon section of the catheter. The cell delivery catheter has been demonstrated not to affect cell viability or other cell properties.
Study: NCT03418233
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to the placebo group will receive Placebos consist 0.9% NaCl and 5% albumin injections (in the same volumes as CardioCell) via the coronary arter(ies)/bypass grafts. The CardioCell and placebo are distributed encoded, in an indistinguishable form.
Study: NCT00877487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule (identical to drug capsules) per day for 4 weeks during the double blind period.
Study: NCT01167933
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd
Study: NCT02841280
Drug: Chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a forced-titration study and the study drug will be increased if goal BP is not achieved (dosage of chlorthalidone not to exceed 50 mg)
Study: NCT02841280
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a forced-titration study and placebo will be increased if goal BP is not achieved.
Study: NCT02246179
Drug: AHES
Normalized name: STOMAHESIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application at test region 1 and 3 under occlusion for 10 minutes
Study: NCT04934579
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 6 cycles will be prescribed.
Study: NCT01127282
Drug: Placebo (digestive tablet)
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (digestive tablet) 1T po for 5 days in addition to anti-viral agent and antipyretics
Study: NCT03963232
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT01354145
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 200 mg/day, 24 months treatment period
Study: NCT02832128
Drug: AUT00063
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules of 200 mg AUT00063, to take orally with food for 4 weeks
Study: NCT02832128
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules of placebo, to take orally with food for 4 weeks
Study: NCT00734578
Drug: SPD503-AM
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPD503 (Guanfacine Extended Release)-AM Optimized 1-4mg
Study: NCT00734578
Drug: SPD503-PM
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPD503 (Guanfacine Extended Release)-PM Optimized 1-4mg
Study: NCT00734578
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to Guanfacine Hydrochloride Extended Release
Study: NCT04094207
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets PLUS Risperidone 2 mg tablet up to 6 mg/day
Study: NCT02586038
Drug: MLN9708
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02586038
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00207584
Drug: Doxycycline treatment
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00053989
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: injection
Study: NCT00239967
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02679040
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy treatment
Study: NCT01820559
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT00166296
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 15 mg/day, starting 2 weeks before and for 12 weeks during interferon therapy.
Study: NCT04304352
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Metronomic Capecitabine 500 mg, thrice daily
Study: NCT04304352
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Metronomic Cyclophosphamide 50 mg daily
Study: NCT01440686
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, oral administrations
Study: NCT04433234
Drug: DS-5141b
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via subcutaneous injection once weekly
Study: NCT00742092
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo capsules matching in appearance miglustat capsules given t.i.d. (three times a day) for 7 days and a single dose on Day 8
Study: NCT02141763
Drug: UCB4940 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous
Study: NCT02141763
Drug: UCB4940 80 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous
Study: NCT02141763
Drug: UCB4940 160 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous
Study: NCT02141763
Drug: UCB4940 240 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous
Study: NCT02141763
Drug: UCB4940 320 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous
Study: NCT02141763
Drug: UCB4940 560 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous
Study: NCT02693028
Drug: Probiotic lozenges
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: The women participating in the study will take two probiotic lozenges per day (morning and evening) after meals.Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
Study: NCT02693028
Drug: Placebo lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: The women participating in the study will take two placebo lozenges per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
Study: NCT02693028
Drug: Probiotic chewing gum
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: The women participating in the study will take two probiotic chewing gums per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
Study: NCT02729051
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This intervention is available in one strip. The strip contains lactose. The formulation is available as dry white powder. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (1 strip with 30 blisters).
Study: NCT00530127
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same dose and frequency as treatment
Study: NCT00530127
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same dosage and frequency as study drug
Study: NCT03687684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-831 Matching Placebo Tablets.
Study: NCT01584167
Drug: Cold crystalloid infusions, 0.9%NaCl or Ringer's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
Study: NCT01273298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be assigned to bisoprolol per os or matching placebo per os daily for 14 days. Bisoprolol will be initiated at a dose of 2.5mg daily for the first two days then up-titrated to 5mg daily for two other days. And finally, bisoprolol will be up-titrated to 10mg daily for the remaining 10 days.
Study: NCT01577953
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three consecutive ascending dose groups (A, B, and C) are planned, with a total of 24 patients with asthma. Each dose group will consist of 8 patients (n=6 receiving active drug and n=2 receiving placebo). Each patient will participate in one dose group only.~Dose escalation to the second and third dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control, up to 4 hours after administration) of the preceding dose group by the Safety Board.
Study: NCT02147158
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet.
Study: NCT00002837
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002837
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04371146
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo pill is administered once using a randomized placebo-controlled between subject's design